<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Inotuzumab ozogamicin (CMC-544), an antibody-targeted chemotherapeutic agent composed of an anti-CD22 antibody conjugated to calicheamicin, a potent cytotoxic antibiotic, specifically targets the CD22 antigen present in &gt;90% of B-lymphoid <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, rendering it useful for treating patients with B-cell non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (B-NHL) </plain></SENT>
<SENT sid="1" pm="."><plain>This phase I study evaluated the safety, tolerability, efficacy, and pharmacokinetics of inotuzumab ozogamicin in Japanese patients </plain></SENT>
<SENT sid="2" pm="."><plain>Eligible patients had relapsed or refractory CD22-positive B-NHL without major organ dysfunction </plain></SENT>
<SENT sid="3" pm="."><plain>Inotuzumab ozogamicin was administered intravenously once every 28 days (dose escalation: 1.3 and 1.8 mg/m(2)) </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> 13 patients had follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, were previously treated with &gt; or =1 rituximab-alone or rituximab-containing chemotherapy, and were enrolled into two dose cohorts (1.3 mg/m(2), three patients; 1.8 mg/m(2), 10 patients) </plain></SENT>
<SENT sid="5" pm="."><plain>No patient had dose-limiting toxicities, and the maximum tolerated dose, previously determined in non-Japanese patients (1.8 mg/m(2)), was confirmed </plain></SENT>
<SENT sid="6" pm="."><plain>Drug-related adverse events (AEs) included <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> (100%), <z:hpo ids='HP_0001882'>leukopenia</z:hpo> (92%), <z:hpo ids='HP_0001888'>lymphopenia</z:hpo> (85%), <z:hpo ids='HP_0001875'>neutropenia</z:hpo> (85%), elevated AST (85%), <z:hpo ids='HP_0002039'>anorexia</z:hpo> (85%), and <z:hpo ids='HP_0002018'>nausea</z:hpo> (77%) </plain></SENT>
<SENT sid="7" pm="."><plain>Grade 3/4 drug-related AEs in &gt; or =15% patients were <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> (54%), <z:hpo ids='HP_0001888'>lymphopenia</z:hpo> (31%), <z:hpo ids='HP_0001875'>neutropenia</z:hpo> (31%), and <z:hpo ids='HP_0001882'>leukopenia</z:hpo> (15%) </plain></SENT>
<SENT sid="8" pm="."><plain>The AUC and C(max) of inotuzumab ozogamicin increased dose-dependently with pharmacokinetic profiles similar to non-Japanese </plain></SENT>
<SENT sid="9" pm="."><plain>Seven patients had complete response (CR, 54%) including unconfirmed CR, four patients had partial response (31%), and two patients had stable disease (15%) </plain></SENT>
<SENT sid="10" pm="."><plain>The overall response rate was 85% (11/13) </plain></SENT>
<SENT sid="11" pm="."><plain>Inotuzumab ozogamicin was well tolerated at doses up to 1.8 mg/m(2) and showed preliminary evidence of activity in relapsed or refractory follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> pretreated with rituximab-containing therapy, warranting further investigations </plain></SENT>
<SENT sid="12" pm="."><plain>This trial was registered in ClinicalTrials.gov (NCT00717925) </plain></SENT>
</text></document>